TD-1792 + Vancomycin

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Staphylococcal Skin Infection

Conditions

Staphylococcal Skin Infection

Trial Timeline

Dec 1, 2006 → May 1, 2007

NCT ID

NCT00442832

About TD-1792 + Vancomycin

TD-1792 + Vancomycin is a phase 2 stage product being developed by Theravance Biopharma for Staphylococcal Skin Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT00442832. Target conditions include Staphylococcal Skin Infection.

What happened to similar drugs?

4 of 5 similar drugs in Staphylococcal Skin Infection were approved

Approved (4) Terminated (2) Active (1)

✅Daptomycin + VancomycinMerckApproved

✅DaptomycinNovartisApproved

✅TigecyclinePfizerApproved

🔄Daptomycin 4 mg/kg + Comparator: vancomycin + Daptomycin 6 mg/kgMerckPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00442832	Phase 2	Completed	Dec 1, 2006	May 1, 2007	Staphylococcal Skin Infection

Competing Products

20 competing products in Staphylococcal Skin Infection

See all competitors

Product	Company	Stage	Hype Score
Ceftobiprole	Johnson & Johnson	Phase 1	29
Ceftobiprole	Johnson & Johnson	Phase 1	29
Daptomycin + Vancomycin	Merck	Approved	35
Daptomycin 4 mg/kg + Comparator: vancomycin + Daptomycin 6 mg/kg	Merck	Phase 3	40
V710 + Placebo	Merck	Phase 1	29
V710 + Comparator: Placebo	Merck	Phase 1	29
V710 (30 µg) with MAA + V710 (30 µg) without MAA	Merck	Phase 1	29
Daptomycin + Vancomycin	Merck	Approved	43
Daptomycin	Novartis	Approved	35
SA4Ag vaccine	Pfizer	Phase 1	29
Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine	Pfizer	Phase 2	27
linezolid (Zyvox)	Pfizer	Pre-clinical	26
Staphylococcus aureus 4-antigen vaccine + Placebo	Pfizer	Phase 2	35
Tigecycline	Pfizer	Approved	43
SA4Ag vaccine low dose + SA4Ag vaccine mid dose + SA4Ag vaccine high dose + Placebo	Pfizer	Phase 1	29
SA4Ag vaccine low dose + SA4Ag vaccine mid dose + SA4Ag vaccine high dose + SA3Ag vaccine + Placebo	Pfizer	Phase 1	29
NDV-3 vaccine with alum IM + NDV-3 vaccine without alum IM + Placebo with alum IM + NDV-3 vaccine without alum ID	United Therapeutics	Phase 1	26
NDV-3 investigational vaccine	United Therapeutics	Phase 1	26
Ceftobiprole	Basilea Pharmaceutica	Phase 1	23
human lactoferrin peptide 1-11	AM-Pharma	Phase 1/2	14